GSK, a British pharmaceutical company, has announced promising results from late-stage studies of its experimental drug, bepirovirsen, aimed at treating chronic hepatitis B. The drug has shown potential in helping nearly one in five patients achieve a functional cure, offering hope for a finite treatment course as an alternative to lifelong antiviral medication.

Study Results and Implications

The studies revealed that six months of treatment with bepirovirsen enabled 19% of patients, who initially had surface antigen levels of 3,000 international units per millilitre (IU/ml) or below, to achieve a functional cure. This means these patients were able to remain off treatment for at least six months, with both hepatitis B virus DNA and surface antigen levels dropping below detectable levels. The response rate increased to 26% among patients with lower surface antigen levels of 1,000 IU/ml or below.

These findings are significant, as current standard-of-care treatments only help 1% to 4% of patients achieve sustained virus clearance. The drug’s potential to provide a functional cure could lead to its broad adoption, as analysts had anticipated a 15% to 20% response rate would be noteworthy.

Regulatory Approval and Market Potential

GSK has sought regulatory approval for bepirovirsen in several major markets, including the United States, Japan, China, and Europe, with a decision from the U.S. expected by October 26. The company is optimistic about the drug’s market potential, projecting peak annual sales of over £2 billion, contributing to its goal of achieving more than £40 billion in annual revenue by 2031.

Dr. Seng Gee Lim, the lead investigator of the studies, expressed optimism about the drug’s impact, stating that achieving a functional cure with just six months of injections represents a significant advancement in managing chronic hepatitis B. He also noted that the drug was generally well tolerated, with most side effects limited to mild injection-site reactions.

Global Impact

With over 250 million people worldwide living with chronic hepatitis B, the development of a treatment that offers a functional cure could have a profound impact on global health. Bepirovirsen’s success in clinical trials marks a hopeful step forward in addressing a disease that has long required lifelong management.

Original reporting: Appleton, WI News Feed (HLL/CB) — read the source article.